Incidence increasing along with number of patients who are overweight or obese.
Associated with increased cardiovascular risk.
May cause acute pancreatitis when fasting levels >5.7 mmol/L (500 mg/dL).
Treatment includes lifestyle modification for all patients.
Statins are generally first-line pharmacotherapy in patients with triglycerides <5.69 mmol/L (<500 mg/dL) in the presence of ≥2 cardiac risk factors.
Fibric acid derivatives, fish oils, and/or nicotinic acid may be added to statins, to achieve targets, in patients with triglycerides <5.69 mmol/L (<500 mg/dL), or as first-line therapy in those with triglycerides ≥5.69 mmol/L (≥500 mg/dL).
Hypertriglyceridaemia is defined by the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) as fasting plasma triglyceride level ≥2.3 mmol/L (≥200 mg/dL). Borderline high is defined as 150 to 199 mg/dL, high as 200 to 499 mg/dL, and very high as ≥500 mg/dL.   Chylomicronaemia is present when triglyceride level is ≥11.3 mmol/L (≥1000 mg/dL).
Professor of Medicine
Playa Vista Medical Center
DAL is an author of several references cited in this monograph.
Use of this content is subject to our disclaimer